Single-Use Modules Expedite Total Solutions 

As the biopharmaceutical industry continues to grow at a rapid pace, companies are realizing that they may need to transform their biomanufac-turing networks to respond to changing market dynamics and anticipate customer requirements. A major factor behind the growth of the biopharma-ceutical industry has been the huge and continued success of the monoclonal antibodies segment. Within the industry, however, companies have started to diversify their pipelines, developing products such as antibody-drug conju-gates, non-antibody recombinant proteins, gene therapies, and autologous and allogenic cell therapies.

Click here to access white paper